For the roughly 1-in-5,000 adults carrying mutations in desmosomal proteins, arrhythmogenic right ventricular cardiomyopathy (ARVC) remains one of the most feared causes of sudden cardiac death in young people—largely because the fibrofatty replacement of heart muscle that drives arrhythmias has lacked a clear, druggable molecular explanation. This research identifies a specific mechanistic chain that may finally change that calculus.
Using models of desmocollin-2 (DSC2) deficiency—a desmosomal cadherin whose mutations are implicated in ARVC—investigators traced how loss of this structural protein activates transforming growth factor-beta 2 (TGF-β2) signaling to accelerate pathological cardiac fibrosis in the right ventricle. DSC2 deficiency appears to disinhibit TGF-β2 pathway activity, triggering downstream fibrogenic cascades that remodel myocardial architecture. The finding positions TGF-β2 not merely as a bystander inflammatory mediator but as a mechanistically central driver of the fibrotic phenotype specific to DSC2-deficient ARVC.
This work fits into a growing body of evidence implicating TGF-β isoforms—particularly TGF-β1—in cardiac fibrosis across multiple cardiomyopathies, but the specific role of the TGF-β2 isoform in ARVC has been undercharacterized. Distinguishing between isoforms matters clinically because TGF-β1 and TGF-β2 have overlapping yet non-identical receptor affinities and downstream signaling profiles, meaning isoform-targeted therapies could offer more precise intervention with fewer off-target effects. The broader TGF-β inhibition space already has compounds in clinical pipelines for fibrotic diseases, making translational application conceivable. Key limitations include the early-stage nature of the mechanistic work—validation in human cardiac tissue and patient-derived models will be essential before any therapeutic claims can be made. Nonetheless, for a condition where treatment options remain largely palliative, identifying TGF-β2 as a targetable node represents a meaningful incremental advance with genuine translational potential.